Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Evaluation of criteria for clinical control in a prospective, international, multicenter study of patients with COPD.

Miravitlles M, Sliwinski P, Rhee CK, Costello RW, Carter V, Tan J, Lapperre TS, Alcazar B, Gouder C, Esquinas C, García-Rivero JL, Kemppinen A, Tee A, Roman-Rodríguez M, Soler-Cataluña JJ, Price DB.

Respir Med. 2018 Mar;136:8-14. doi: 10.1016/j.rmed.2018.01.019. Epub 2018 Jan 31.

PMID:
29501251
2.

Factors affecting the selection of an inhaler device for COPD and the ideal device for different patient profiles. Results of EPOCA Delphi consensus.

Miravitlles M, Soler-Cataluña JJ, Alcázar B, Viejo JL, García-Río F.

Pulm Pharmacol Ther. 2018 Feb;48:97-103. doi: 10.1016/j.pupt.2017.10.006. Epub 2017 Oct 12.

PMID:
29031616
3.

Requirements, Strengths and Weaknesses of Inhaler Devices for COPD Patients from the Expert Prescribers' Point of View: Results of the EPOCA Delphi Consensus.

García-Río F, Soler-Cataluña JJ, Alcazar B, Viejo JL, Miravitlles M.

COPD. 2017 Dec;14(6):573-580. doi: 10.1080/15412555.2017.1365120. Epub 2017 Sep 11.

PMID:
28891722
4.

Validating the Concept of COPD Control: A Real-world Cohort Study from the United Kingdom.

Nibber A, Chisholm A, Soler-Cataluña JJ, Alcazar B, Price D, Miravitlles M.

COPD. 2017 Oct;14(5):504-512. doi: 10.1080/15412555.2017.1350154. Epub 2017 Aug 16.

PMID:
28813176
5.

Active smoking and COPD phenotype: distribution and impact on prognostic factors.

Riesco JA, Alcázar B, Trigueros JA, Campuzano A, Pérez J, Lorenzo JL.

Int J Chron Obstruct Pulmon Dis. 2017 Jul 6;12:1989-1999. doi: 10.2147/COPD.S135344. eCollection 2017.

6.

Expert Statement on the Single-Agent Use of Inhaled Bronchodilator in the Treatment of Stable Mild-Moderate Chronic Obstructive Pulmonary Disease.

Riesco Miranda JA, Alcázar B, Alfageme I, Casanova C, Celli B, de-Torres JP, Jiménez Ruiz CA.

Arch Bronconeumol. 2017 Oct;53(10):574-582. doi: 10.1016/j.arbres.2017.03.022. Epub 2017 May 9. Review. English, Spanish.

7.

Evaluation of symptomatic patients without airflow obstruction: back to the future.

Lopez-Campos JL, Alcazar B.

J Thorac Dis. 2016 Dec;8(12):E1657-E1660. doi: 10.21037/jtd.2016.12.103. No abstract available.

8.

The evaluation of a remote support program on quality of life and evolution of disease in COPD patients with frequent exacerbations.

Alcazar B, de Lucas P, Soriano JB, Fernández-Nistal A, Fuster A, González-Moro JM, Arnedillo A, Sidro PG, de Los Monteros MJ.

BMC Pulm Med. 2016 Nov 8;16(1):140.

9.

What pulmonologists think about the asthma-COPD overlap syndrome.

Miravitlles M, Alcázar B, Alvarez FJ, Bazús T, Calle M, Casanova C, Cisneros C, de-Torres JP, Entrenas LM, Esteban C, García-Sidro P, Cosio BG, Huerta A, Iriberri M, Izquierdo JL, López-Viña A, López-Campos JL, Martínez-Moragón E, Pérez de Llano L, Perpiñá M, Ros JA, Serrano J, Soler-Cataluña JJ, Torrego A, Urrutia I, Plaza V.

Int J Chron Obstruct Pulmon Dis. 2015 Jul 15;10:1321-30. doi: 10.2147/COPD.S88667. eCollection 2015.

10.

Generic utilities in chronic obstructive pulmonary disease patients stratified according to different staging systems.

Miravitlles M, Huerta A, Fernández-Villar JA, Alcázar B, Villa G, Forné C, Cuesta M, Crespo C, García-Río F.

Health Qual Life Outcomes. 2014 Sep 5;12:120. doi: 10.1186/s12955-014-0120-5.

11.

Report of 38 cases of tracheobronchitis in non-immunocompromised patients with dual isolation of Aspergillus in lower respiratory tract samples.

Barberán J, Sánchez-Haya E, del Castillo D, Sanz F, Alcázar B, Malmierca E; ASP Investigator Group.

Rev Esp Quimioter. 2014 Jun;27(2):110-4.

12.

Multicentric study on the beta-blocker use and relation with exacerbations in COPD.

Puente-Maestu L, Calle M, Ortega-González A, Fuster A, González C, Márquez-Martín E, Marcos-Rodriguez PJ, Calero C, Rodríguez-Hermosa JL, Malo de Molina R, Aburto M, Sobradillo P, Alcázar B, Tirado-Conde G; GEMEPOC Group.

Respir Med. 2014 May;108(5):737-44. doi: 10.1016/j.rmed.2014.02.009. Epub 2014 Feb 20.

13.

Repeated Aspergillus isolation in respiratory samples from non-immunocompromised patients not selected based on clinical diagnoses: colonisation or infection?

Barberan J, Alcazar B, Malmierca E, Garcia de la Llana F, Dorca J, Del Castillo D, Villena V, Hernandez-Febles M, Garcia-Perez FJ, Granizo JJ, Gimenez MJ, Aguilar L; ASP Investigator Group.

BMC Infect Dis. 2012 Nov 12;12:295. doi: 10.1186/1471-2334-12-295.

14.

Factors associated with hospital admission for exacerbation of chronic obstructive pulmonary disease.

Alcázar B, García-Polo C, Herrejón A, Ruiz LA, de Miguel J, Ros JA, García-Sidro P, Conde GT, López-Campos JL, Martínez C, Costán J, Bonnin M, Mayoralas S, Miravitlles M.

Arch Bronconeumol. 2012 Mar;48(3):70-6. doi: 10.1016/j.arbres.2011.10.009. Epub 2011 Dec 21. English, Spanish.

15.

Neuropsychological functioning associated with high-altitude exposure.

Virués-Ortega J, Buela-Casal G, Garrido E, Alcázar B.

Neuropsychol Rev. 2004 Dec;14(4):197-224. Review.

PMID:
15796116
16.

Purification of allergens by high-performance liquid chromatography. IV. Purification of the allergen of olive pollen (Olea europea).

Rubio N, Brieva A, Alcazar B.

J Chromatogr. 1987 Aug 21;403:312-8. No abstract available.

PMID:
3680417

Supplemental Content

Loading ...
Support Center